1. Patent Eligibility and the Natural Product Doctrine
The Supreme Court's decision in Association for Molecular Pathology v. Myriad Genetics established that isolated natural products are not automatically patentable merely because they have been extracted or purified. This ruling created significant uncertainty for nutraceutical patent claims. A compound derived from a plant or mineral may be rejected by the U.S. Patent and Trademark Office if examiners view it as an unmodified product of nature, even if significant effort and expense went into its isolation.
Distinguishing Patentable Formulations from Natural Products
Courts examine whether a nutraceutical formulation or process demonstrates a "markedly different" characteristic from what exists in nature. A synergistic blend of ingredients, a novel bioavailability enhancement, or a proprietary extraction method that yields a materially different result may overcome the natural product barrier. Conversely, simply combining well-known ingredients in conventional proportions will likely fail eligibility review. From a practitioner's perspective, the difference between a rejected application and an allowed one often hinges on how carefully the claims are drafted to emphasize non-obvious structural or functional distinctions.
Strategic Patent Claim Construction
Successful nutraceutical patent applications typically narrow claims to specific formulations, dosage ranges, or methods of use rather than claiming the active ingredient itself. Claims that recite a particular combination with unexpected results, or a delivery mechanism that solves a technical problem, stand a stronger chance of surviving USPTO examination. Real-world outcomes depend heavily on how thoroughly the specification documents the inventive concept and distinguishes it from prior art and naturally occurring substances.
2. Fda Regulatory Overlap and Patent Scope
Nutraceutical patents operate in a regulatory environment where the FDA classifies products as dietary supplements, conventional foods, or drugs depending on structure and intended use claims. This classification directly affects patent strategy because a product marketed as a dietary supplement may face different patentability standards than one positioned as a pharmaceutical. Patent claims that are too broad or that recite drug-like therapeutic benefits can trigger FDA scrutiny, or even conflict with the dietary supplement regulatory framework.
Navigating Claim Scope and Regulatory Risk
A patent claim that explicitly recites treating, curing, or preventing disease language may be rejected as directed to an unpatentable method of treatment, or may create regulatory liability if the product is marketed as a supplement. Conversely, claims focused on structure, composition, or functional parameters (e.g., bioavailability, stability) are often more defensible. The interplay between patent prosecution strategy and regulatory positioning requires coordinated planning early in product development.
3. Trade Secrets and Complementary Protection
Many nutraceutical companies rely on trade secret protection alongside, or instead of, patents. Proprietary formulations, manufacturing processes, and quality control protocols that are not disclosed in patent applications remain protectable under the Defend Trade Secrets Act and New York Uniform Trade Secrets Act. This dual-protection approach is particularly valuable when patent eligibility is uncertain, or when the competitive advantage depends on process know-how rather than a final product composition.
Enforcing Trade Secrets in New York Court
New York courts apply the Uniform Trade Secrets Act definition: information that derives economic value from not being generally known and is subject to reasonable efforts to maintain secrecy. In trade secret misappropriation cases filed in the Southern District of New York or New York State courts, plaintiffs must prove both the existence of a qualifying trade secret and that the defendant acquired or used it through improper means (e.g., breach of confidentiality, theft, or breach of fiduciary duty). The practical significance is that trade secret claims often proceed faster than patent litigation, and may yield damages for unjust enrichment without requiring the plaintiff to prove patent validity or infringement of a specific claim.
4. Infringement Disputes and Defensive Strategies
When a company receives a cease-and-desist letter or patent infringement allegation in the nutraceutical space, the response strategy depends on whether the patent is likely valid and whether the accused product actually falls within the patent claims. Invalidity defenses often focus on prior art (particularly prior dietary supplement formulations or published research), the natural product doctrine, or improper claim scope. Designing around a patent by reformulating the product or narrowing marketing claims may be faster and less expensive than litigation.
Prior Art and Invalidity Challenges
Nutraceutical patents are vulnerable to prior art rejections because the industry has a long history of traditional formulations, published research on ingredient combinations, and prior commercial products. An effective invalidity defense often requires identifying published references that disclose the same or substantially similar formulation, and demonstrating that the combination was obvious to a person skilled in the art. Patent litigation in federal court can be costly; early assessment of invalidity risk is critical to determining whether to settle, design around, or litigate.
Regulatory and Compliance Considerations
Before launching a nutraceutical product or responding to an infringement claim, confirm that all marketing claims, labeling, and ingredient sourcing comply with FDA and FTC regulations. A product that infringes a patent but also violates FDA or FTC rules creates compounded legal exposure. Additionally, patent and data rights protections may extend to clinical study data or regulatory submissions if those assets are properly secured and documented.
5. Strategic Considerations before Litigation or Licensing
Nutraceutical patent disputes often resolve through licensing agreements rather than full litigation because the cost of patent litigation (typically $2 million to $5 million) can exceed the product's profit margin. Parties should evaluate early whether a cross-license, royalty arrangement, or covenant not to sue is preferable to prolonged court proceedings. Additionally, consider whether the patent holder has actually commercialized the invention or is primarily enforcing it against competitors; courts may view non-practicing entity enforcement differently in damages calculations.
| Strategy | Timeline | Cost Range |
| Design Around | 3–6 months | $50K–$200K |
| Settlement/License | 6–12 months | $100K–$500K |
| Full Patent Litigation | 2–4 years | $2M–$5M+ |
The decision between these paths depends on the strength of the patent, the accused product's market potential, and the company's risk tolerance. Early engagement with counsel experienced in both patent prosecution and nutraceutical regulation will clarify which strategy aligns with your business objectives and legal exposure.
20 Jan, 2026
